Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M105008200 on July 30, 2001

J. Biol. Chem., Vol. 276, Issue 40, 37120-37123, October 5, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/40/37120    most recent
M105008200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Are 5-Hydroxytryptamine-preloaded beta -Cells an Appropriate Physiologic Model System for Establishing That Insulin Stimulates Insulin Secretion?*

Walter S. ZawalichDagger, Gregory J. Tesz, and Kathleen C. Zawalich

From the Yale University School of Nursing, New Haven, Connecticut 06536-0740

Received for publication, May 31, 2001, and in revised form, July 24, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The release and oxidation of 5-hydroxytryptamine from 5-hydroxytryptamine-preloaded beta -cells has been used as a surrogate marker for insulin secretion. Findings made using this methodology have been used to support the concept that insulin stimulates its own release. In the present studies, the effects of 5-hydroxytryptamine on stimulated insulin secretion from isolated perifused rat islets was determined. When added together with stimulatory glucose, 5-hydroxytryptamine (0.5 mM) significantly reduced both phases of 8 mM glucose-induced secretion and reduced the first phase of 15 mM glucose-induced release by 60% without any effect on sustained insulin release rates. Preloading of beta -cells with 0.5 mM 5-hydroxytryptamine for 3 h resulted in a more severe impairment of 15 mM glucose-induced secretion. First and second phase release rates were reduced by 70 and 55%, respectively. In addition, this pretreatment protocol also abolished 200 µM tolbutamide-induced insulin secretion from perifused islets. These findings confirm that 5-hydroxytryptamine is a powerful inhibitor of stimulated insulin secretion. The responses of 5-hydroxytryptamine-preloaded beta -cells may not accurately reflect the biochemical events occurring during the physiologic regulation of insulin secretion. The suggestion that insulin stimulates its own secretion based exclusively on amperometric measurements should be reconsidered.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The concept that insulin exerts biochemical and physiologic effects on the cell that secretes it, the pancreatic beta -cell, has been suggested based on a number of observations. Over 30 years ago (1, 2), a negative feedback effect of insulin on its own release was proposed. A large number of subsequent studies (3-9) in which insulin or connecting peptide levels were measured arrived at a similar conclusion. We recently reported (10), in agreement with several prior studies (11, 12), that the phosphatidylinositol 3-kinase (PI3K)1 inhibitor wortmannin amplified glucose-induced insulin secretion. This conclusion was based upon insulin secretion measurements from isolated perifused rat islets that retain physiologic insulin secretory responses similar to those observed using the perfused rat pancreas preparation (13-15). We also suggested that an impairment in PI3K signaling in beta -cells might be responsible for the hyperinsulinemia noted in a variety of insulin-resistant states including obesity and type 2 diabetes. Thus, whereas disruption of PI3K signaling results in insulin resistance in peripheral insulin-dependent tissues (16, 17), the same biochemical alteration in the beta -cell results in compensatory hyperinsulinemia. This elegant communications network allows the beta -cell to match the degree of insulin resistance and the secretion of insulin thus maintaining glucose tolerance. This concept presupposes that insulin exerts a negative feedback effect on its own secretion and utilizes the same biochemical signaling systems described in liver, muscle, and adipose tissues (18-20).

In contrast to the numerous studies demonstrating that insulin inhibits its own secretion (1-9), it has been suggested most recently that insulin stimulates insulin secretion from the beta -cell (21). Amperometrically measured spikes of 5-hydroxytryptamine (5HT) release from beta -cells preincubated in 0.5 mM 5HT for 16 h provided the experimental support for this concept. This method takes advantage of the fact that amperometric measurements of 5HT release from preloaded beta -cells can be used as a surrogate marker for insulin release and has been utilized by several groups (21-26). It is based upon earlier studies in which 5HT was found to be localized in islet secretory granules and thought to be cosecreted with insulin (27). Not all reports, however, agreed with this concept (28). Unfortunately in none of the electrophysiologic studies (21-26) was glucose-induced insulin secretion actually assessed to corroborate the amperometric analyses, and despite previous studies demonstrating an adverse effect of 5HT on insulin secretion (29, 30), the possibility that 5HT preloading might negatively affect secretion was not examined in any of these amperometry studies.

In an attempt to resolve the opposite concepts with regard to the inhibitory or stimulatory effects of insulin on beta -cell secretion, we conducted studies with islets treated with 0.5 mM 5HT. In agreement with several previous studies (29, 30), we observed that 5HT exerts profound acute and long lasting inhibitory effects on glucose-induced insulin secretion from perifused rat islets. It also abolished tolbutamide-induced secretion as well. The concept that amperometric measurements of 5HT release from beta -cells reflect the physiologic regulation of insulin secretion should be reconsidered.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Islet Isolation-- The detailed methodologies employed to assess insulin output from collagenase-isolated rat islets have been described previously (10, 31). Male Harlan Sprague-Dawley rats (350-475 g) were purchased from Charles River Laboratories, Inc. (Wilmington, MA). All animals were treated in a manner that complied with the NIH Guidelines for the Care and Use of Laboratory Animals (41). The animals were fed ad libitum. After intraperitoneal Nembutal (pentobarbital sodium, 50 mg/kg; Abbott, North Chicago, IL)-induced anesthesia, islets were isolated by collagenase digestion and hand-picked, using a glass loop pipette, under a stereo microscope. They were free of exocrine contamination.

Preloading Studies with 5HT-- After isolation, groups of 16-18 islets were loaded onto nylon filters (Tetko, Inc., Briarcliff Manor, NY), placed in small glass vials, and incubated for 3 h in 400 µl of a Krebs-Ringer bicarbonate (KRB) solution containing 0.5 mM 5HT plus 5 mM glucose. This solution, oxygenated and warmed (37 °C), was gently added to the vial with islets. The vial was capped with a rubber stopper and gassed for 10 s with 95% O2, 5%CO2. The vials were again gently oxygenated after 90 min. After the preloading period, the islets still on nylon filters were washed with 5 ml of fresh KRB and perifused as described below.

Perifusion Studies-- Groups of 14-18 freshly isolated or preincubated islets were perifused with KRB at a flow rate of 1 ml/min for 30 min, usually with 3 mM glucose, to establish basal and stable insulin secretory rates. In some experiments 0.5 mM 5HT was included during this period. After this 30-min stabilization period they were then perifused with the appropriate agonist or agonist combinations as indicated in the figure legends and under "Results." Perifusate solutions were gassed with 95% O2, 5% CO2 and maintained at 37 °C. Insulin released into the medium was measured by radioimmunoassay (32).

Reagents-- Hanks' solution was used for the islet isolation. The perifusion medium consisted of 115 mM NaCl, 5 mM KCl, 2.2 mM CaCl2, 1 mM MgCl2, 24 mM NaHCO3, and 0.17 g/dl bovine serum albumin. The 125I-labeled insulin used for the insulin assay was purchased from PerkinElmer Life Sciences. Bovine serum albumin (radioimmunoassay grade), glucose, 5-HT hydrochloride, and the salts used to make the Hanks' solution and perifusion medium were purchased from Sigma. Rat insulin standard (lot 615-ZS-157) was the generous gift of Dr. Gerald Gold, Eli Lilly Co. (Indianapolis, IN). Collagenase (Type P) was obtained from Roche Molecular Biochemicals.

Statistics-- Statistical significance was determined using the Student's t test for unpaired data or analysis of variance in conjunction with the Newman-Keuls test for unpaired data. A p value less than or equal to 0.05 was taken as significant. Values presented in the figures and under "Results" represent means ± S.E. of at least three observations.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Acute 5HT Exposure Studies-- In the initial series of experiments islets were perifused immediately after isolation. In response to 8 mM glucose, insulin secretory rates increased most significantly during the final 20 min of the perifusion (Fig. 1, top panel). For example, 20, 30, or 40 min after the onset of stimulation with 8 mM glucose, secretory rates averaged 159 ± 14, 199 ± 25, or 214 ± 18 pg/islet/min (n = 6). The inclusion of 5HT during the stimulatory period with 8 mM glucose significantly reduced islet insulin secretory responses. For example, 20, 30, or 40 min after the onset of stimulation with 8 mM glucose, secretory rates now averaged 87 ± 20, 102 ± 15, or 112 ± 12 pg/islet/min (n = 4). Peak first phase release noted during the initial minutes of 8 mM glucose stimulation was also impaired by the inclusion of 0.5 mM 5HT. They averaged 89 ± 7 pg/islet/min from control islets and 62 ± 6 pg/islet/min from islets stimulated with the combination of 8 mM glucose plus 5HT.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Insulin secretion from perifused rat islets. Groups of islets were perifused immediately after isolation. They were perifused with 3 mM glucose (G3) for 30 min to establish stable, basal rates of release. Top panel, one group (open circles, n = 6) was then stimulated for 40 min with 8 mM glucose (G8) alone. The second group (closed circles, n = 4) was stimulated with 8 mM glucose in the additional presence of 0.5 mM 5HT. Bottom panel, one group (open circles, n = 8) was then stimulated for 40 min with 15 mM glucose (G15) alone. The second group (closed circles, n = 5) was stimulated with 15 mM glucose in the additional presence of 0.5 mM 5HT. Mean values ± S.E. are given in this and subsequent figures. The asterisk indicates a significant difference between groups at this time point. This and subsequent perifusion figures have not been corrected for the dead space in the perifusion apparatus, 2.5 ml or 2.5 min with a flow rate of 1 ml/min.

When stimulated with 15 mM glucose, control islets responded with a brisk biphasic insulin secretory response (Fig. 1, bottom panel). Peak first phase secretion averaged 177 ± 21 pg/islet/min whereas release rates measured 35-40 min after the onset of stimulation increased to 834 ± 80 pg/islet/min (n = 8). The presence of 0.5 mM 5HT during stimulation with 15 mM glucose significantly reduced peak first phase secretion, which fell from 177 ± 21 pg/islet/min from control islets to 76 ± 9 pg/islet/min (n = 4) in the presence of 5HT, a reduction of ~60%. Rates of insulin secretion during the final 20 min of stimulation with 15 mM glucose (745 ± 32 pg/islet/min) were comparable with those from control islets.

Effects of Prior Exposure to 5HT on Stimulated Insulin Secretion-- In the amperometric studies in which 5HT oxidation was used as the index of insulin secretion (21-26), cells were pretreated with 0.5 mM 5HT for 4-16 h and stimulated with various agonists including tolbutamide. In the next series of studies, we explored the impact of prior exposure to 5HT on insulin secretion. Two different protocols were employed. In the first series of studies, 0.5 mM 5HT was included together with 3 mM glucose only during the initial 30-min stabilization period of the perifusion with 3 mM glucose. Similar to the amperometric studies conducted with 5HT-preloaded islets (21, 24, 25), there was no washout period prior to stimulation (Fig. 2) The results are given in Fig. 2 and demonstrate that a brief prior exposure to 0.5 mM 5HT exerted a significant and sustained inhibitory effect on 15 mM glucose-induced secretion. Most dramatic was the reduction in peak first phase secretion, which was decreased to 49 ± 14 pg/islet/min (n = 4). The impact of 5HT on secretion was evident during the entire 40-min stimulatory period with 15 mM glucose alone. Thus, despite its absence from the perifusion medium for 40 min, the adverse effect of 5HT on release is sustained.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Prior short term exposure to 5HT impairs 15 mM glucose-induced insulin secretion. Groups of islets were perifused immediately after isolation. The control group (open circles) was perifused with 3 mM glucose alone (G3) for 30 min to establish stable, basal rates of release. The second group (closed circles) was perifused with the combination of 3 mM glucose plus 0.5 mM 5-HT for 30 min. Both groups were then stimulated with 15 mM glucose alone for 40 min. The 15 mM control data (open circles) are the same as those depicted in Fig. 1. The asterisk indicates a significant difference between groups at this time point.

In the next series of experiments, islets were first exposed to 0.5 mM 5HT for 3 h. This period of preexposure was chosen because longer culture periods result in a deterioration of glucose-induced secretion (33-35), a situation that might complicate interpretation of the findings. The islets were then perifused for 30 min with 3 mM glucose alone prior to stimulation. The results are presented in Fig. 3. In response to 200 µM tolbutamide a small increase in secretion from control islets was observed only during the initial few minutes of stimulation (Fig. 3, top panel). This agrees with previous studies that have demonstrated a marked glucose dependence for the insulin stimulatory effect of sulfonylurea (36-38). After prior exposure to 0.5 mM 5HT for 3 h, this minimal secretory response was abolished.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Preloading islets with 5HT for 3 h reduces tolbutamide- and 15 mM glucose-induced secretion. Groups of islets were isolated, loaded onto nylon filters, and incubated for 3 h in a KRB solution supplemented with 5 mM glucose. In one group (closed triangles) 0.5 mM 5HT was included during this 3-h period. Islets were washed with 5 ml of fresh KRB. Top panel, islets (n = 5 for both groups) were perifused for 30 min with 3 mM glucose and for an additional 30 min with 3 mM glucose plus 200 µM tolbutamide. Only the first 10 min of the insulin secretory response to the sulfonylurea are depicted. Bottom panel, islets (n = 9 for controls and n = 5 for 5HT-pretreated) were perifused for 30 min with 3 mM glucose and for an additional 40 min with 15 mM glucose. The asterisk indicates a significant difference between groups at this time point.

In response to 15 mM glucose, control islets responded with a biphasic insulin secretory response (Fig. 3, bottom panel). First phase release averaged 196 ± 21 pg/islet/min whereas sustained rates of secretion averaged 570 ± 57 pg/islet/min (n = 9) during the final 5 min of stimulation. Similar to the findings made when 5HT-preloaded islets were stimulated with tolbutamide, the response to 15 mM glucose was significantly reduced by a 3-h exposure to 5HT. Most dramatic was the reduction in the first phase response, which declined from 196 ± 21 pg/islet/min to 60 ± 16 pg/islet/min (n = 5). The adverse effect of 5HT preexposure on glucose-induced insulin release was sustained for at least 70 min. Release rates measured 35-40 min after the onset of 15 mM glucose were still significantly less than control islet responses. They averaged 240 ± 38 pg/islet/min in the 5HT-pretreated islets at this time point.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In an attempt to improve the time resolution between the electrical and secretory events that participate in insulin release, several groups have employed amperometry (21-24, 26). This technique has also been applied to insulin receptor substrate-1 gene-disrupted beta -cells as well (25). Initially employed in studies using adrenal chromaffin cells (39), secretion is detected with this methodology by a carbon fiber electrode placed next to the cell of interest. As described by Ashcroft and co-workers (23) "the electrode is held at or above the oxidation potential of the secreted compound and secretion monitored by the current associated with the oxidation of the vesicle contents." The method is only applicable to readily oxidized compounds, but unfortunately, insulin is not such a compound. To circumvent this shortcoming of insulin, these groups have preloaded beta -cells for 4-16 h with 5HT, a highly electroactive compound (21-24, 26). Because it appears to be confined to secretory granules, it has been assumed in these amperometric studies that the secretion of 5HT accurately reflects the physiologic secretion of insulin. Unfortunately, in none of these aforementioned beta -cell amperometric studies was insulin secretion actually measured. It was assumed to occur in parallel with the amperometric changes induced by the oxidation of 5HT. In the present series of experiments, insulin secretion from perifused rat islets was measured during acute exposure to or after a 30-min to 3-h preloading period with 5HT. The level of 5HT (0.5 mM) employed was identical to that used in the amperometric studies. The exposure times to 5HT were not as prolonged. However, considering the time-dependent inhibitory actions of 5HT noted in our studies, the adverse effects of more prolonged exposure to 5HT on stimulated secretion may be even more severe than demonstrated here.

In response to 8 mM glucose, a modest insulin secretory response was evoked from control rat islets. Second phase release rates after 40 min of stimulation were increased 4-6-fold above prestimulatory rates whereas the initial response, although modest, was approximately doubled. The inclusion of 5HT together with 8 mM glucose significantly reduced both phases of 8 mM glucose-induced secretion. Using a higher glucose level (15 mM) resulted in a more pronounced first phase response and a large rising second phase response from control islets. Inclusion of 5HT during acute stimulation with 15 mM glucose reduced the peak first phase response by about 60%. Sustained second phase release rates were comparable with control values.

Preexposure to 0.5 mM 5HT for either 30 min or 3 h resulted in a profound suppression of both phases of 15 mM glucose-induced release. Thus, in agreement with previous studies using mouse islets (29, 30), 5HT is a powerful inhibitor of the insulin secretory response to glucose.

In a recent report (21) and in contrast to other studies in which insulin or connecting peptide levels were measured (1-7, 9), it was concluded based on amperometric measurements of 5HT release that insulin stimulates its own secretion. In addition to insulin, 16-h 5HT-preloaded beta -cells were also stimulated with 200 µM tolbutamide in the presence of 3 mM glucose. We performed additional studies utilizing this stimulatory protocol using islets preloaded with 5HT for 3 h. Islets were perifused and stimulated with 200 µM tolbutamide in the presence of 3 mM glucose. Consistent with previous studies using the perfused rat pancreas (36) or perifused islets (38), a small, transient, and minimal insulin secretory response that rapidly subsided was observed. Under conditions employed in these studies and in which insulin secretion rates were measured, prior exposure to 0.5 mM 5HT for 3 h abolished this weak response to tolbutamide.

What is the experimental basis for suggesting that 5HT secretion mirrors physiologic insulin release? One of the earliest studies with 5HT (28) demonstrated that neither 20 mM glucose nor the sulfonylurea glibenclamide mobilized granule-bound 5HT. In fact these two compounds tended to inhibit the efflux of 5HT under conditions in which they both stimulated insulin secretion measured in parallel studies. Other secretion studies demonstrated that 5HT profoundly reduced stimulated insulin secretion (29, 30). In a subsequent report (27), a small, transient increase in 5HT release was observed from perifused mouse islets. One bothersome issue regarding the use of 5HT as a barometer of insulin secretion is that 11 mM glucose alone failed to increase 5HT release in most cells studied by Ashcroft and co-workers (23). Forskolin (10 µM) had to be included together with glucose. In rat islets at least, 10 mM glucose is a powerful stimulant of insulin secretion in the absence of forskolin (40).

According to Aspinwall et al. (24), "Substantial evidence now exists that demonstrates that 5HT is loaded primarily into secretory vesicles and that 5HT is co-secreted with insulin by exocytosis (22, 23, 26)." The references supporting this claim were all amperometric studies unsubstantiated by actual insulin secretory measurements. Our data indicate that 5HT is a powerful inhibitor of the release process and that results obtained with 5HT have to be interpreted cautiously.

In conclusion, our studies and several previous reports (29, 30) demonstrate that prior exposure of beta -cells to 5HT results in a profound time-dependent suppression of the insulin secretory process. The concept that the secretion of 5HT from preloaded beta -cells reflects physiologic secretion is not supported by these or other studies (28-30). It is premature to conclude that insulin, under physiologic conditions, stimulates its own secretion based exclusively on studies using amperometric measurements of 5HT release without substantial corroborating data including actual measurements of insulin secretion from 5HT-preloaded beta -cells.

    FOOTNOTES

* These studies were supported by NIDDK, National Institutes of Health Grant 41230 and by the American Diabetes Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Yale University School of Nursing, P. O. Box 9740, 100 Church St. South, New Haven, CT 06536-0740. Tel.: 203-785-5522; Fax: 203-785-6455; E-mail: walter.zawalich@yale.edu.

Published, JBC Papers in Press, July 30, 2001, DOI 10.1074/jbc.M105008200

    ABBREVIATIONS

The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; 5HT, 5-hydroxytryptamine; KRB, Krebs-Ringer bicarbonate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sodoyez, J.-C., Sodoyez-Goffaux, F., and Foà, P. P. (1969) Proc. Soc. Exp. Biol. 130, 568-571
2. Iversen, J., and Miles, D. W. (1971) Diabetes 20, 1-9
3. Rappaport, A. M., Ohira, S., Coddling, J. A., Empey, G., Kalnins, A., Lin, B. J., and Haist, R. E. (1972) Endocrinology 91, 168-176
4. Liljenquist, J. E., Horwitz, D. L., Jennings, A. S., Chiasson, J. L., Keller, U., and Rubenstein, A. H. (1978) Diabetes 27, 563-570
5. Ammon, H. P. T., and Verspohl, E. (1976) Endocrinology 99, 1469-1476
6. Loreti, L., Dunbar, J. C., Chen, S., and Foà, P. P. (1974) Diabetologia 10, 309-315
7. Robinson, C., Tamborlane, W. V., Maggs, D. G., Enoksson, S., Sherwin, R. S., Silver, D., Shulman, G. I., and Caprio, S. (1998) Am. J. Physiol. 274, E737-E743
8. Ammon, H. P., Reiber, C., and Verspohl, E. J. (1991) J. Endocrinol. 128, 27-34
9. Argoud, G. M., Schade, D. S., and Eaton, R. P. (1987) Diabetes 36, 959-962
10. Zawalich, W. S., and Zawalich, K. C. (2000) Endocrinology 141, 3287-3295
11. Hagiwara, S., Sakurai, T., Tashiro, F., Hashimoto, Y., Matsuda, Y., Nonomura, Y., and Miyazaki, J. (1995) Biochem. Biophys. Res. Commun. 214, 51-59
12. Nunoi, K., Yasuda, K., Tanaka, H., Kubota, A., Okamoto, Y., Adachi, T., Shihara, N., Uno, M., Xu, L. m., Kagimoto, S., Seino, Y., Yamada, Y., and Tsuda, K. (2000) Biochem. Biophys. Res. Commun. 270, 798-805
13. Gerich, J. E., Charles, M. A., and Grodsky, G. M. (1974) J. Clin. Invest. 54, 833-841
14. Curry, D. L. (1986) Endocrinology 118, 170-175
15. Pagliara, A. S., Stillings, S. N., Hover, B., Martin, D. M., and Matschinsky, F. M. (1974) J. Clin. Invest. 54, 819-932
16. Kim, Y.-B., Nikoulina, S. E., Ciaraldi, T. P., Henry, R. R., and Kahn, B. B. (1999) J. Clin. Invest. 104, 733-741
17. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., and Mandarino, L. J. (2000) J. Clin. Invest. 105, 311-320
18. Virkamäki, A., Ueki, K., and Kahn, C. R. (1999) J. Clin. Invest. 103, 931-943
19. Kahn, B. B., and Flier, S. J. (2000) J. Clin. Invest. 106, 473-480
20. Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Anderson, D. K., Hundal, R. S., Rothman, D. L., Petersen, K. F., and Shulman, G. I. (1999) J. Clin. Invest. 103, 253-259
21. Aspinwall, C. A., Lakey, J. R. T., and Kennedy, R. T. (1999) J. Biol. Chem. 274, 6360-6365
22. Smith, P., Duchen, M., and Ashcroft, F. M. (1994) J. Physiol. (Lond.) 475P, 157
23. Smith, P. A., Duchen, M. R., and Ashcroft, F. M. (1995) Pflügers Arch. Eur. J. Physiol. 430, 808-818
24. Aspinwall, C. A., Brooks, S. A., Kennedy, R. T., and Lakey, J. R. T. (1997) J. Biol. Chem. 272, 31308-31314
25. Aspinwall, C. A., Qian, W.-J., Roper, M. G., Kulkarni, R. N., Kahn, C. R., and Kennedy, R. T. (2000) J. Biol. Chem. 275, 22331-22338
26. Zhou, Z., and Misler, S. (1996) J. Biol. Chem. 270, 270-277
27. Gylfe, E. (1978) J. Endocrinol. 78, 239-248
28. Hellman, B., Lernmark, A., Sehlin, J., and Täljedal, I.-B. (1972) Biochem. Pharmacol. 21, 695-706
29. Lernmark, A. (1971) Horm. Metab. Res. 3, 305-309
30. Gagliardino, J. J., Nierle, C., and Pfeiffer, E. F. (1974) Diabetologia 10, 411-414
31. Zawalich, W. S., and Zawalich, K. C. (2000) J. Endocrinol. 166, 111-120
32. Albano, J. D. M., Ekins, R. P., Maritz, G., and Turner, R. C. (1972) Acta Endocrinol. 70, 487-509
33. Malaisse-Lagae, F., Sener, A., and Malaisse, W. J. (1987) Acta Diabetol. Lat. 24, 17-25
34. Metz, S. A. (1988) Diabetes 37, 3-7
35. Zawalich, W. S., Zawalich, K. C., and Kelley, G. G. (1995) Acta Diabetol. 32, 158-164
36. Grodsky, G. M., G. H., E., Fanska, R., and Karam, J. H. (1977) Fed. Proc. 36, 2714-2719
37. Curry, D. L., Bennett, L. L., and Grodsky, G. M. (1968) Endocrinology 83, 572-584
38. Zawalich, W. S., and Zawalich, K. C. (1988) Diabetes 37, 816-823
39. Chow, R. H., Ruden, L., and Neher, E. (1992) Nature 356, 60-63
40. Zawalich, W. S., Bonnet-Eymard, M., and Zawalich, K. C. (2000) Metabolism 49, 1156-1163
41. National Institutes of Health. (1985) NIH Guidelines for the Care and Use of Laboratory Animals, NIH Publication No. 85-23 , National Institutes of Health, Bethesda, MD


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Physiol.Home page
L. Eliasson, F. Abdulkader, M. Braun, J. Galvanovskis, M. B. Hoppa, and P. Rorsman
Novel aspects of the molecular mechanisms controlling insulin secretion
J. Physiol., July 15, 2008; 586(14): 3313 - 3324.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
P. E. MacDonald and P. Rorsman
The Ins and Outs of Secretion from Pancreatic {beta}-Cells: Control of Single-Vesicle Exo- and Endocytosis
Physiology, April 1, 2007; 22(2): 113 - 121.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. I. Hagren and A. Tengholm
Glucose and Insulin Synergistically Activate Phosphatidylinositol 3-Kinase to Trigger Oscillations of Phosphatidylinositol 3,4,5-Trisphosphate in beta-Cells
J. Biol. Chem., December 22, 2006; 281(51): 39121 - 39127.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
G. G. Holz
Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic {beta}-Cell
Diabetes, January 1, 2004; 53(1): 5 - 13.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Srivastava and H. J. Goren
Insulin Constitutively Secreted by {beta}-Cells Is Necessary for Glucose-Stimulated Insulin Secretion
Diabetes, August 1, 2003; 52(8): 2049 - 2056.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Kang, J. W. Joseph, O. G. Chepurny, M. Monaco, M. B. Wheeler, J. L. Bos, F. Schwede, H.-G. Genieser, and G. G. Holz
Epac-selective cAMP Analog 8-pCPT-2'-O-Me-cAMP as a Stimulus for Ca2+-induced Ca2+ Release and Exocytosis in Pancreatic beta -Cells
J. Biol. Chem., February 28, 2003; 278(10): 8279 - 8285.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. Kang and G. G Holz
Amplification of exocytosis by Ca2+-induced Ca2+ release in INS-1 pancreatic {beta} cells
J. Physiol., January 1, 2003; 546(1): 175 - 189.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. J. Barker, I. B. Leibiger, B. Leibiger, and P.-O. Berggren
Phosphorylated inositol compounds in beta -cell stimulus-response coupling
Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1113 - E1122.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
F. Thevenod
Ion channels in secretory granules of the pancreas and their role in exocytosis and release of secretory proteins
Am J Physiol Cell Physiol, September 1, 2002; 283(3): C651 - C672.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. S. Zawalich and K. C. Zawalich
Effects of Glucose, Exogenous Insulin, and Carbachol on C-peptide and Insulin Secretion from Isolated Perifused Rat Islets
J. Biol. Chem., July 12, 2002; 277(29): 26233 - 26237.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/40/37120    most recent
M105008200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement